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Abstract:
Cardiac dysfunction(CD) is a significant cause of delayed deaths in trauma-haemorrhagic shock patients. It is associated with poor outcomes and no treatments
are available. Adenosine, via the mediation of its A2A receptor, could potentially alleviate such CD. This study investigates the efficacy of adenosine and
regadenoson, an adenosine A2A receptor agonist, as a novel cardiovascular protective resuscitation approach in a preclinical trauma-haemorrhage model. A
murine pressure-controlled haemorrhagic shock model was dosed with adenosine (54µg/g) or regadenoson (10 or 30µ/g) during the initial post-injury
echocardiography-guided resuscitation (1h post-injury) (n=15/group). Cardiovascular function (Echocardiography/MAP) and lactate were assessed up to 3 hours
post-injury and terminal samples were analysed for myocardial injury markers. A control group was only dosed with crystalloid. Animals receiving adenosine and
regadenoson (30µg/g) demonstrated significant improvement survival outcomes and the maintenance of cardiac output, compared to controls (80% and 87% vs
40%, and 11.64 + 3.4 mL/min, 12.05 + 2.2 mL/min vs 7.66 + 3.8mL/min, all p<0.05). Additionally, these animals also required lower volumes of resuscitation fluid
to restore stroke volume (47.9 + 7.0 µL/g and 34.9 + 10.8 µL/g vs 63.8 + 7.5 µL/g, p<0.05), improving systemic perfusion with lower lactate levels (4.6 + 0.9
mmol/L and 4.4 + 1.5 mmol/L vs 6.6 + 2.6 mmol/L, p<0.05). Animals receiving high-dose regadenoson showed a significant lower cardiac injury biomarker h-FABP
level (1548.8±442.6 vs 2465.0±650.2 ng/mL, p<0.05). It also significantly reduced infiltration of neutrophils and apoptotic myocardial injury (0.5±0.1% vs 0.8±0.3
Ly6G, p=0,038 and 0.63 ±0.24% vs 2.50 ± 1.17 % Caspase 3, p = 0.0224). In conclusion, the administration of regadenoson during resuscitation improves
physiological outcomes, alleviating trauma-induced cardiac injury and impacting positively on survival. 
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